{"prompt": "['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', 'should be informed of all subjects withdrawn/discontinued for this reason. If there are multiple', 'reasons for early withdrawal/discontinuation, the worst case scenario should be chosen.', '12.6.', 'Unscheduled Visit', 'An unscheduled visit (or telephone follow-up) may be performed at any time during the study at', \"the subject's request or as deemed necessary by the Investigator. The date and reason for the\", 'unscheduled visit will be recorded on the CRF/eCRF as well as any other data obtained (eg, AEs,', 'concomitant medications/treatments, and results from procedures or tests).', '12.7.', 'Follow-Up Visit', 'No Follow-up Visit is planned for this study.', '13.', 'STATISTICS', 'The statistical analysis will be coordinated by the responsible Sponsor biostatistician (or', 'designee at the Contract Research Organization [CRO]). The Statistical Analysis Plan (SAP)', 'will be written to provide details of the analyses, along with specifications for tables, listings,', 'and figures to be produced. The SAP will be finalized before the database lock at the latest. If', 'there are differences, the information in the SAP will supersede the information in the protocol.', 'Any changes from the analyses planned in the SAP will be justified in the CSR.', 'All analyses will be performed by the Sponsor (or designee CRO) using STATISTICAL', 'ANALYSIS SOFTWARE Version 9.3 or above.', 'In general, all data will be summarized with descriptive statistics (number of subjects, mean, and', 'standard deviation [SD], minimum, median, and maximum) for continuous variables and', 'frequency and percentage for categorical variables.', '13.1.', 'Sample Size', 'A sample size of 382 evaluable subjects, allocated 1:1, will provide 90% power to detect a', 'between-group mean difference (GSP 301 NS vs placebo NS) of 1.0 in the absolute change from', 'baseline in average AM and PM subject-reported 12-hour rTNSS over a 14-day treatment period', '(assuming a 2-sided alpha of 5%). A standard deviation of 3.0 in the change from baseline in', '12-hour rTNSS over a 14-day treatment period has been assumed. Assuming a drop-out rate of', '15%, a total of approximately 450 subjects are planned to be randomized (225 subjects in each', 'treatment group). Depending on the actual drop-out rate, the Sponsor may decide to randomize', 'higher or lower number of subjects in order to meet the required sample size of 382 evaluable', 'subjects.', '13.2.', 'Analysis Sets', 'Detailed criteria for analysis sets will be documented in the SAP and the allocation of subjects to', 'analysis sets will be determined prior to database hard-lock.', 'Glenmark', 'CONFIDENTIAL', 'Page 60 of 90']['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', '13.2.1.', 'Full Analysis Set', 'The FAS will consist of all subjects who are randomized and receive at least 1 dose of IP and', 'have at least 1 post-baseline primary efficacy assessment. This will be the primary analysis set', 'for efficacy analyses.', '13.2.1.1. Per Protocol Set', 'The Per Protocol Set (PPS) will consist of the subset of the FAS who do not meet criteria for', 'PPS exclusion.', '13.2.1.2. Safety Analysis Set', 'The Safety Analysis Set (SAS) will consist of all subjects who are randomized and receive at', 'least one dose of IP. This will be the analysis set for safety analyses.', '13.3.', 'Endpoints', '13.3.1.', 'Primary Endpoint', 'Change from baseline in average AM and PM subject-reported 12-hour rTNSS over the 14-day', 'treatment period.', '13.3.2.', 'Secondary Enppoints', 'Change from baseline in average AM and PM subject-reported 12-hour instantaneous', 'Total Nasal Symptom Score (iTNSS) over the 14-day treatment period.', 'Change from baseline in the overall Pediatric Rhinoconjunctivitis Quality of Life', 'Questionnaire (PRQLQ) score on Day 15 (Visit 4) between treatment groups.', 'Change from baseline in average AM and PM subject-reported 12-hour reflective', 'Total Ocular Symptom Score (rTOSS) over the 14-day treatment period.', '13.3.3.', 'Other Enppoints', 'Nasal symptoms:', 'Change from baseline in AM subject-reported rTNSS over the 14-day treatment', 'period.', 'Change from baseline in AM subject-reported iTNSS over the 14-day treatment', 'period.', 'Change from baseline in PM subject-reported rTNSS over the 14-day treatment', 'period.', 'Change from baseline in PM subject-reported iTNSS over the 14-day treatment', 'period.', 'Change from baseline in subject-reported reflective individual nasal symptoms over', 'the 14-day treatment period (AM, PM and average of AM and PM).', 'Glenmark', 'CONFIDENTIAL', 'Page 61 of 90']\n\n###\n\n", "completion": "END"}